Safety, pharmacokinetics, and early bactericidal activity of quabodepistat in combination with delamanid, bedaquiline, or both in adults with pulmonary tuberculosis: a randomised, active-controlled, open-label trial
InfectologiaSobre o estudo
- Desenho
- Ensaio clínico randomizado
- Nível de evidência
- 2 · Nova evidência
- Revista
- The Lancet. Infectious diseases
- Publicado em
- 26 nov 2024
- Citações
- 18
O resumo deste estudo é do publisher e não tem licença aberta: por isso mostramos aqui só os dados do estudo, e o texto fica na fonte original, nos links abaixo.
O estudo original
Safety, pharmacokinetics, and early bactericidal activity of quabodepistat in combination with delamanid, bedaquiline, or both in adults with pulmonary tuberculosis: a randomised, active-controlled, open-label trial
Rodney Dawson, Andreas H Diacon, Veronique de Jager, Kim Narunsky, V Mischka Moodley, Kelly W Stinson, Yongge Liu, Bo Zheng, Jeffrey Hafkin
Descritores MeSH
- Tuberculosis, Pulmonary
- Antitubercular Agents
- Oxazoles
- Diarylquinolines
- Nitroimidazoles
- Ethylenediamines
- Ethambutol
- Adult
- Isoniazid
- Drug Therapy, Combination
Veja também
Estudos relacionados
- A Pragmatic Trial of a 6-Month Strategy for Rifampicin-Resistant Tuberculosis
- Bedaquiline-pretomanid-moxifloxacin-pyrazinamide for drug-sensitive and drug-resistant pulmonary tuberculosis treatment: a phase 2c, open-label, multicentre, partially randomised controlled trial
- Efficacy and safety of 8-week regimens for the treatment of rifampicin-susceptible pulmonary tuberculosis (TRUNCATE-TB): a prespecified exploratory analysis of a multi-arm, multi-stage, open-label, randomised controlled trial
- Efficacy and safety of a 4-month quabodepistat, delamanid, and bedaquiline regimen for drug-susceptible pulmonary tuberculosis: a multicentre, open-label, randomised, proof-of-concept, non-inferiority, phase 2b/c trial